It’s harder than ever to realise the potential of life-transforming medicines

Research shows that 7 out of 10 healthcare brands underperform expectations at launch, despite increased investment in scientific innovation

Of those brands that underperform, one third miss their forecasts by more than 40%

Brands need to move fast to execute the game-changing strategies that mark the difference between underperformance and exceptional outcomes

McKinsey & Company. (2013). Beyond the storm: Launch excellence in the new normal (p. 4).
Retrieved from https://www.mckinsey.com

The reality: once assets or brands perform below expectations, the majority continue to underperform in the years to come

Of the assets and brands that miss forecasts in Year 1

78%

78% will go on to miss forecast in Year 2

70%

70% will go on to miss forecast in Year 3

Lucid staff 3

What we do

We build sustained partnerships and work fast to deliver results that matter for clients and healthcare brands of all sizes

We develop new clinical standards and consensus guidelines across dozens of disease states

We shift clinical perspectives, establish new treatment targets and help build new growth markets

We deliver accelerated pathways to market through streamlined product development and commercialisation strategies

Our deep expertise in the asset lifecycle enables us to create transformational outcomes for some of the most important brands in the industry

20+

20+ years of experience transforming assets into breakthrough brands that change lives

100+

100+ launches of the world's biggest and most innovative high-science, breakthrough medicines

#1

Unparalleled record of building a #1 HCP recommended status for OTC and CPG brands

Are you ready to transform the potential of your asset or brand?

Explore case studies